NIH Funds $4 Million Study to Unravel Why Weight Returns After Stopping GLP-1 Drugs

A team of researchers at UTHealth Houston has received a five-year, $4 million grant from the National Institutes of Health to tackle one of the most frustrating problems in modern obesity medicine: the rapid and often unpredictable weight regain that follows the discontinuation of GLP-1 receptor agonist medications. The study, led by principal investigator Absalon Gutierrez, MD, a professor in the Division of Endocrinology, Diabetes, and Metabolism at McGovern Medical School, will search for genetic markers that may explain why some patients rebound after stopping these wildly popular drugs while others manage to hold on to their weight loss. The work is being conducted in partnership with Vanderbilt University and the Border Health Research Center at UTHealth Houston School of Public Health in Brownsville, and it promises to shine a light on a biological mystery that has grown more urgent as millions of people around the world begin, and eventually stop, taking GLP-1 therapies.

The clinical stakes could hardly be higher. GLP-1 receptor agonists, which mimic the gut hormone glucagon-like peptide-1 to suppress appetite and improve metabolic control, are not permanent cures for obesity. According to research cited by the UTHealth Houston team, roughly 30 percent of patients stop taking the medications within six months, and about 50 percent discontinue within a year. The consequences of stopping are stark: most individuals regain more than 60 percent of the weight they lost within a single year of discontinuation. That rebound is not merely cosmetic. Along with the returning pounds come the return of serious health risks, including type 2 diabetes and cardiovascular complications, erasing many of the therapeutic gains that made these drugs so transformative in the first place.

What intrigues scientists most is that the rebound is not uniform. Not everyone regains weight at the same rate, and not everyone sees their metabolic health deteriorate equally after stopping treatment. This variability has led researchers to hypothesize that the body may retain a kind of metabolic memory, molecular traces of the medication or of the previous weight loss that continue to influence how metabolism behaves long after the last injection. If such memory exists and can be measured, it could fundamentally change how doctors prescribe these drugs, helping them identify in advance which patients are genetically predisposed to regain weight and which might safely taper off therapy.

At the heart of the new grant is the phenomenon of weight cycling, the repeated loss and regain of body weight associated with stopping and restarting any weight loss strategy, whether pharmacological, dietary, or surgical. The rebound effect is driven by complex physiological adaptations that evolution engineered to defend body weight: appetite surges, energy expenditure drops, and hormonal shifts conspire to restore lost fat stores. Weight cycling can also exact its own toll, contributing to muscle loss, a slowing of resting metabolism, and strain on the cardiometabolic system. Understanding the genetic and molecular underpinnings of this cycle, the researchers argue, is essential to breaking it.

The study itself is a rigorously designed double-blind randomized trial involving 100 participants with obesity drawn from the Border Health Research Cohort. Each participant will receive semaglutide, one of the most widely prescribed GLP-1 receptor agonists, for six months. After that initial treatment period, half of the group will be randomly selected to discontinue the medication while the other half will remain on GLP-1 therapy. This design allows the investigators to compare, under controlled and blinded conditions, what happens in the bodies of people who stop the drug versus those who continue it, isolating the biological consequences of withdrawal from the natural variability of weight and metabolism.

Researchers will analyze genetic markers in both groups, focusing on markers related to insulin metabolism, energy expenditure, appetite hormones, and body composition. These markers could serve as predictors of therapeutic durability, telling clinicians early on whether a given patient is likely to maintain the benefits of treatment after stopping. The population under study is also significant. The Border Health Research Center, established in 2003, specializes in studying risk factors for obesity, diabetes, and related complications among Americans of Mexican descent living in the Lower Rio Grande Valley, a community that has been historically underrepresented in metabolic research despite carrying a substantial burden of cardiometabolic disease.

To capture what happens to the body at every stage of stopping and starting GLP-1 medications, the team will take small fat tissue and blood samples and examine how gene activity changes after the drug is withdrawn. They will measure circulating molecules, gene expression patterns, and immune signals to track how energy use and metabolism shift in the absence of the medication. Participants will also receive a standardized test meal, allowing the researchers to measure in real time how blood sugar, insulin response, and appetite behave once the drug’s pharmacological grip is released. These dynamic measurements go far beyond what a simple scale can reveal, offering a molecular-level view of the rebound process as it unfolds.

Throughout the trial, participants will undergo whole-body scans to assess changes in body composition, distinguishing fat loss from muscle loss, along with breathing tests that measure resting calorie burn, a direct readout of metabolic rate. Detailed surveys will track diet and exercise habits, ensuring that behavioral factors can be accounted for when interpreting the biological data. Together, these measurements will build a comprehensive picture of how discontinuation reshapes metabolism, from the activity of individual genes in fat tissue to the whole-body balance of energy intake and expenditure.

Co-principal investigator Joseph B. McCormick, MD, professor of epidemiology at the School of Public Health, who holds the James H. Steele, DVM, Professorship, emphasized the clinical significance of the problem. According to McCormick, weight regain after GLP-1 receptor agonist discontinuation is a significant clinical challenge, and this randomized, blinded trial will help uncover why some people regain weight while others do not, including the possibility of a metabolic memory of the initial treatment. He noted that because controlled molecular studies of GLP-1 receptor agonist exposure and withdrawal have not previously been reported, the work could identify new drug targets and predictive biomarkers of therapeutic durability in an understudied population. In other words, the trial may be the first of its kind to watch, molecule by molecule, what happens when these drugs are withdrawn under controlled conditions.

By pinpointing the molecular changes that occur in fat tissue and blood after discontinuation, the researchers hope to uncover new biological targets for future treatments that could prevent weight rebound altogether. The ultimate goal is to help doctors preserve the long-term health benefits of weight loss even after medication stops, transforming GLP-1 therapy from a treatment that works only as long as it is taken into one whose benefits can be understood, predicted, and perhaps extended. For the millions of patients who have experienced the discouragement of regaining hard-lost weight, and for the clinicians trying to guide them, the answers emerging from this Houston-led trial could mark the beginning of a more durable era in obesity medicine.

Subject of Research: Genetic and molecular determinants of weight regain after discontinuation of GLP-1 receptor agonist therapy

Article Title: NIH awards $4 million grant to study GLP-1 weight regain

Article References: NIH awards $4 million grant to study GLP-1 weight regain. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: GLP-1 receptor agonists, weight regain, obesity, semaglutide, genetic markers, metabolic memory, weight cycling, NIH grant, UTHealth Houston, endocrinology, randomized trial, cardiometabolic health